CoChat

Cell-Autonomous and Non–Cell-Autonomous Mechanisms of Transformation by Amplified FGFR1 in Lung Cancer

Malchers, Florian, Dietlein, Felix, Schöttle, Jakob, Lu, Xin, Nogova, Lucia, Albus, Kerstin, Fernandez-Cuesta, Lynnette, Heuckmann, Johannes M., Gautschi, Oliver, Diebold, Joachim, Plenker, Dennis, Gardizi, Masyar, Scheffler, Matthias, Bos, Marc, Seidel, Danila, Leenders, Frauke, Richters, André, Peifer, Martin, Florin, Alexandra, Mainkar, Prathama S., Karre, Nagaraju, Chandrasekhar, Srivari, George, Julie, Silling, Steffi, Rauh, Daniel, Zander, Thomas, Ullrich, Roland T., Reinhardt, H. Christian, Ringeisen, Francois, Büttner, Reinhard, Heukamp, Lukas C., Wolf, Jürgen, Thomas, Roman K. · 2014 · Cancer Discovery
Cited by 94

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Abstract

The 8p12 locus (containing the FGFR1 tyrosine kinase gene) is frequently amplified in squamous cell lung cancer. However, it is currently unknown which of the 8p12-amplified tumors are also sensitive to fibroblast growth factor receptor (FGFR) inhibition. We found that, in contrast with other recurrent amplifications, the 8p12 region included multiple centers of amplification, suggesting marked genomic heterogeneity. FGFR1-amplified tumor cells were dependent on FGFR ligands in vitro and in vivo. Furthermore, ectopic expression of FGFR1 was oncogenic, which was enhanced by expression of MYC. We found that MYC was coexpressed in 40% of FGFR1-amplified tumors. Tumor cells coexpressing MYC were more sensitive to FGFR inhibition, suggesting that patients with FGFR1-amplified and MYC-overexpressing tumors may benefit from FGFR inhibitor therapy. Thus, both cell-autonomous and non–cell-autonomous mechanisms of transformation modulate FGFR dependency in FGFR1-amplified lung cancer, which may have implications for patient selection for treatment with FGFR inhibitors. Significance: Amplification of FGFR1 is one of the most frequent candidate targets in lung cancer. Here, we show that multiple factors affect the tumorigenic potential of FGFR1, thus providing clinical hypotheses for refinement of patient selection. Cancer Discov; 4(2); 246–57. ©2013 AACR. See related commentary by Lockwood and Politi, p. 152 This article is highlighted in the In This Issue feature, p. 131

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/2159-8290.cd-13-0323

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 94

Metadata

Authors
Malchers, F., Dietlein, F., Schöttle, J., Lu, X., Nogova, L., Albus, K., Fernandez-Cuesta, L., Heuckmann, J. M., Gautschi, O., Diebold, J., Plenker, D., Gardizi, M., Scheffler, M., Bos, M., Seidel, D., Leenders, F., Richters, A., Peifer, M., Florin, A., Mainkar, P. S., Karre, N., Chandrasekhar, S., George, J., Silling, S., Rauh, D., Zander, T., Ullrich, R. T., Reinhardt, H. C., Ringeisen, F., Büttner, R., Heukamp, L. C., Wolf, J., & Thomas, R. K.
Venue
Cancer Discovery
Published
2014-02-01
Volume
4
Issue
2
Pages
246-257
ISSN
  • 2159-8274 (ISSN-L)
  • 2159-8290
OpenAlex
W2111675538
Cited by
94
References
5
FWCI
5.78
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.